234 related articles for article (PubMed ID: 20148715)
1. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.
Lopez-Guerra M; Colomer D
Expert Opin Ther Targets; 2010 Mar; 14(3):275-88. PubMed ID: 20148715
[TBL] [Abstract][Full Text] [Related]
2. p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.
López-Guerra M; Roué G; Pérez-Galán P; Alonso R; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2009 Apr; 15(8):2767-76. PubMed ID: 19351760
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells.
Pickering BM; de Mel S; Lee M; Howell M; Habens F; Dallman CL; Neville LA; Potter KN; Mann J; Mann DA; Johnson PW; Stevenson FK; Packham G
Oncogene; 2007 Feb; 26(8):1166-77. PubMed ID: 16924235
[TBL] [Abstract][Full Text] [Related]
4. Signalling to drug resistance in CLL.
Hertlein E; Byrd JC
Best Pract Res Clin Haematol; 2010 Mar; 23(1):121-31. PubMed ID: 20620976
[TBL] [Abstract][Full Text] [Related]
5. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
6. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
Hewamana S; Lin TT; Jenkins C; Burnett AK; Jordan CT; Fegan C; Brennan P; Rowntree C; Pepper C
Clin Cancer Res; 2008 Dec; 14(24):8102-11. PubMed ID: 19088025
[TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway.
Ciucci A; Gianferretti P; Piva R; Guyot T; Snape TJ; Roberts SM; Santoro MG
Mol Pharmacol; 2006 Nov; 70(5):1812-21. PubMed ID: 16908599
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of NF-kappaB signaling: 785 and counting.
Gilmore TD; Herscovitch M
Oncogene; 2006 Oct; 25(51):6887-99. PubMed ID: 17072334
[TBL] [Abstract][Full Text] [Related]
9. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
10. Targeting NF-kappaB in hematologic malignancies.
Braun T; Carvalho G; Fabre C; Grosjean J; Fenaux P; Kroemer G
Cell Death Differ; 2006 May; 13(5):748-58. PubMed ID: 16498458
[TBL] [Abstract][Full Text] [Related]
11. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
12. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
13. c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
Lin K; Glenn MA; Harris RJ; Duckworth AD; Dennett S; Cawley JC; Zuzel M; Slupsky JR
Cancer Res; 2006 Aug; 66(15):7801-9. PubMed ID: 16885384
[TBL] [Abstract][Full Text] [Related]
14. Role of Rel/NF-kappaB transcription factors in apoptosis of human hepatocellular carcinoma cells.
Chiao PJ; Na R; Niu J; Sclabas GM; Dong Q; Curley SA
Cancer; 2002 Oct; 95(8):1696-705. PubMed ID: 12365017
[TBL] [Abstract][Full Text] [Related]
15. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
17. Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage.
Fan S; Meng Q; Laterra JJ; Rosen EM
Oncogene; 2007 Jul; 26(33):4774-96. PubMed ID: 17297451
[TBL] [Abstract][Full Text] [Related]
18. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
[TBL] [Abstract][Full Text] [Related]
19. Preclinical assessment of curcumin as a potential therapy for B-CLL.
Everett PC; Meyers JA; Makkinje A; Rabbi M; Lerner A
Am J Hematol; 2007 Jan; 82(1):23-30. PubMed ID: 16947318
[TBL] [Abstract][Full Text] [Related]
20. Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Olivier S; Robe P; Bours V
Biochem Pharmacol; 2006 Oct; 72(9):1054-68. PubMed ID: 16973133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
